Know Cancer

or
forgot password

Serum Proteomic Profiling for the Early Diagnosis of Colorectal Cancer


N/A
18 Years
90 Years
Not Enrolling
Both
Colorectal Neoplasms

Thank you

Trial Information

Serum Proteomic Profiling for the Early Diagnosis of Colorectal Cancer


Magnetic bead-based fractionation coupled with matrix-assisted laser
desorption/ionization-time-of-flight mass spectrometry (MALDI-TOF MS) was used to screen
serum samples from CRC patients and healthy controls.

Inclusion Criteria


Patients with colorectal cancer

Inclusion criteria

- histologically confirmed colorectal cancer

- aged 18 years or older

- have provided written informed consent

Exclusion criteria

- refusal to participate

Healthy controls

Inclusion criteria

- no cancer history

- aged 18 years or older

- have provided written informed consent

Exclusion criteria

- refusal to participate

- have first-degree relative with a known history of colorectal cancer

Type of Study:

Observational

Study Design:

Observational Model: Case Control, Time Perspective: Prospective

Outcome Measure:

Serum peptide mass fingerprinting (PMF)

Outcome Description:

Compare PMF of the colorectal caner group and control group, and then build the model to distinguish patients with colorectal cancer and controls

Outcome Time Frame:

2010.03-2012.05 (2 years)

Safety Issue:

No

Principal Investigator

Jianmin Xu, M.D.,Ph.D.

Investigator Role:

Principal Investigator

Investigator Affiliation:

Fudan University

Authority:

China: National Natural Science Foundation

Study ID:

ZSCG-001

NCT ID:

NCT01604798

Start Date:

January 2007

Completion Date:

May 2012

Related Keywords:

  • Colorectal Neoplasms
  • proteomics
  • serum peptides
  • colorectal cancer
  • MALDI-TOF MS
  • Neoplasms
  • Colorectal Neoplasms

Name

Location